Regeneron Pharmaceuticals, Inc. (BVL:REGN)

Market Cap	268.04B
Revenue (ttm)	49.40B
Net Income (ttm)	15.87B
Shares Out	n/a
EPS (ttm)	144.21
PE Ratio	16.89
Forward PE	16.30
Dividend	12.61 (1.71%)
Ex-Dividend Date	Nov 20, 2025

Volume	n/a
Average Volume	3
Open	n/a
Previous Close	736.90
Day's Range	n/a
52-Week Range	564.51 - 1,057.34
Beta	n/a
RSI	73.21
Earnings Date	Jan 30, 2026

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous sq...

• Industry: Pharmaceutical Preparations
• Founded: 1988
• Employees: 15,106
• Stock Exchange: Lima Stock Exchange
• Ticker Symbol: REGN

Financial Performance

In 2024, Regeneron Pharmaceuticals's revenue was $14.20 billion, an increase of 8.27% compared to the previous year's $13.12 billion. Earnings were $4.41 billion, an increase of 11.61%.

Financial numbers in USD